PTC Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

PTC Therapeutics

31/07/2026 06:43

PTC Therapeutics Inc PTCT.OQ reported quarterly adjusted earnings of 92 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -83 cents.  The mean expectation of fourteen analysts for the quarter was for earnings of 42 cents per share. Wall Street expected results to range from -10 cents to 96 cents per share.
Revenue rose 101.5% to $360.52 million from a year ago; analysts expected $298.96 million. 
PTC Therapeutics Inc's reported EPS for the quarter was 92 cents​.
The company reported quarterly net income of $83.5 million.
PTC Therapeutics Inc shares had fallen by 8.7% this quarter and lost 1.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 300.4% in the last three months.​ 
In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for PTC Therapeutics Inc is $93.00, about 18.8% above its last closing price of $75.52
This summary was machine generated from LSEG data July 31 at 05:43 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.42
0.92
Beat
Mar. 31 2026 
-0.47
-0.03
Beat
Dec. 31 2025 
0.04
-1.67
Missed
Sep. 30 2025 
-1.37
0.20
Beat